Prognostic Indicators in Stage IV Surgically Treated Gastric Cancer Patients: A Retrospective Multi-Institutional Study

2018 ◽  
Vol 36 (4) ◽  
pp. 331-339
Author(s):  
Alberto Biondi ◽  
Domenico D’Ugo ◽  
Ferdinando Cananzi ◽  
Stefano Rausei ◽  
Federico Sicoli ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Residual Disease ◽  
Stage Iv ◽  
Long Term Results ◽  
Stage Iv Gastric Cancer ◽  
Short And Long Term ◽  
Gastric Cancer Patients

Introduction: The role of gastric resection in treating metastatic gastric adenocarcinoma is controversial. In the present study, we reviewed the short- and long-term outcomes of stage IV patients undergoing surgery. Methods: A retrospective review was conducted that assessed patients undergoing elective surgery for incurable gastric carcinoma. Short- and long-term results were evaluated. Results: A total of 122 stage IV gastric cancer patients were assessed. Postoperative mortality was 5.7%, and the overall rate of complications was 35.2%. The overall survival rate at 1 and 3 years was 58 and 19% respectively; the median survival was 14 months. Improved survival was observed for the factors age less than 60 years (p = 0.015), site of metastases (p = 0.022), extended lymph node dissection (p = 0.044), absence of residual disease after surgery (p = 0.001), and administration of adjuvant chemotherapy (p = 0.016). Multivariate analysis showed that residual disease and adjuvant chemotherapy were independent prognostic factors. Conclusions: The results of this study suggest that surgery combined with systemic chemotherapy in selected patients with stage IV gastric cancer can improve survival.

scholarly journals The long-term survival of stage IV gastric cancer patients with conversion therapy

2017 ◽  
Vol 21 (2) ◽  
pp. 315-323 ◽  
Author(s):  
Kazuya Yamaguchi ◽  
Kazuhiro Yoshida ◽  
Toshiyuki Tanahashi ◽  
Takao Takahashi ◽  
Nobuhisa Matsuhashi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Stage Iv ◽  
Conversion Therapy ◽  
Term Survival ◽  
Long Term Survival ◽  
Stage Iv Gastric Cancer ◽  
Gastric Cancer Patients

scholarly journals Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Koichi Hayano ◽  
Hiroki Watanabe ◽  
Takahiro Ryuzaki ◽  
Naoto Sawada ◽  
Gaku Ohira ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Stage Iv ◽  
R0 Resection ◽  
Conversion Surgery ◽  
First Line ◽  
Her2 Positive ◽  
Stage Iv Gastric Cancer ◽  
Gastric Cancer Patients ◽  
First Line Treatment

Abstract Background Since the ToGA trial, trastuzumab-based chemotherapy is the standard treatment for HER2 positive stage IV gastric cancer. However, it is not yet clear whether surgical resection after trastuzumab-based chemotherapy (conversion surgery) can improve survival of HER2 positive stage IV gastric cancer. The purpose of this study is to evaluate the prognostic benefit of conversion surgery in HER2 positive stage IV gastric cancer patients. Case presentation We retrospectively investigated the medical records of the patients with HER2 positive (IHC3(+) or IHC2(+)/FISH(+)) stage IV gastric cancer treated with trastuzumab-based chemotherapy as the first line treatment. Overall survival (OS) was compared between patients with conversion surgery and without. Eleven HER2 positive stage IV gastric cancer patients treated with trastuzumab-based chemotherapy as the first line treatment were evaluated. Response rate was 63.6%, and 6 of 11 patients could receive conversion surgery. R0 resection was achieved in four patients. In Kaplan–Meier analysis, patients who received conversion surgery showed significantly better OS than those without surgery (3-year survival rate, 66.7% vs. 20%, P = 0.03). The median OS of patients who achieved R0 resection is 51.8 months. Conclusions Conversion surgery might have a survival benefit for HER2 positive stage IV gastric cancer patients. If curative surgery is technically possible, conversion surgery could be a treatment option for HER2 positive stage IV gastric cancer.

scholarly journals Monocyte Chemiluminescence Traits in Gastric Cancer

2021 ◽  
Vol 31 (2) ◽  
pp. 34-39
Author(s):  
O. V. Smirnova ◽  
A. A. Sinyakov ◽  
V. V. Tsukanov
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Gastric Adenocarcinoma ◽  
Stage Iv ◽  
Stage I ◽  
Control Cohort ◽  
Chemiluminescence Intensity ◽  
Stage Iv Gastric Cancer ◽  
Spontaneous Chemiluminescence ◽  
Gastric Cancer Patients

Aim. A study of monocyte chemiluminescent activity at variant stages of gastric cancer.Materials and methods. The study enrolled 90 gastric cancer patients and 70 healthy donors. Spontaneous and induced chemiluminescence in monocytes was assessed for 90 min with a “BLM 3607” 36-channel chemiluminescence analyser (Russia). Opsonized zymosan-induced chemiluminescence enhancement was measured as a ratio of the areas under the induced vs. spontaneous chemiluminescence curves, the activation index. Statistical significance was estimated with the Mann—Whitney criterion (p < 0.05).Results. The maximal spontaneous monocyte chemiluminescence intensity significantly decreased in stage IV gastric cancer patients compared to the control cohort (p = 0.035). Time to maximum in spontaneous chemiluminescence increased in all gastric cancer patients vs. control (p = 0.001), and in stage IV gastric cancer vs. stage I patients (p = 0.043). The areas under a curve in spontaneous and induced monocyte chemiluminescence increased in all gastric cancer patients vs. control (p = 0.001), and in stage IV gastric cancer vs. stage I patients (p = 0.037). The activation index was higher in all gastric cancer cases compared to control (p = 0.001).Conclusion. All patients with gastric adenocarcinoma, irrespective of the stage, revealed changes in the monocyte chemiluminescence activity, i.e. a longer time to maximum in spontaneous chemiluminescence and larger area under the curve of spontaneous and induced chemiluminescence, the activation index. Maximal monocyte spontaneous chemiluminescence intensity diminished in stage IV gastric cancer compared to the control cohort. Immune activity reflected in monocyte chemiluminescence correlates with the stage of gastric adenocarcinoma.

Survival benefit of oophorectomy in stage IV gastric cancer patients with Krukenberg tumors.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16566-e16566
Author(s):  
Ahmed Abdelhakeem ◽  
Brian D. Badgwell ◽  
Naruhiko Ikoma ◽  
Larissa Meyer ◽  
Meina Zhao ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Stage Iv ◽  
Primary Objective ◽  
Standard Chemotherapy ◽  
Ovarian Metastases ◽  
Stage Iv Gastric Cancer ◽  
Treatment Data ◽  
Krukenberg Tumors ◽  
Gastric Cancer Patients

e16566 Background: The management of Krukenberg tumors from primary gastric cancer remains unclear and it is unknown if oophorectomy improves survival. The purpose of this study was to compare the overall survival (OS) of patients with ovarian metastases from gastric cancer treated with standard chemotherapy to chemotherapy and oophorectomy. Methods: Between January 2008 and August 2019, we retrospectively analyzed the clinicopathological features and treatment data of 97 patients with stage IV gastric cancer patients with ovarian metastases. Patients were categorized into two groups: Oophorectomy plus standard chemotherapy treatment vs. standard chemotherapy only (non-oophorectomy). The primary objective was to assess OS. Results: A total of 97 patients were identified. 37 (38.1%) patients had oophorectomy and 60 (61.9%) patients did not have oophorectomy. OS was better in the oophorectomy group relative to the non-oophorectomy group (37 months vs. 20 months; P= 0.0554). Survival from the time of diagnosis of ovarian metastases was significantly better in oophorectomy group relative to the non-oophorectomy group (26 months vs. 12 months; P= 0.0006). Conclusions: Our results showed that Oophorectomy in addition to systemic chemotherapy in this unique population seems to confer survival advantage in this retrospective analysis. Prospective evaluation is warranted.

The prognostic significance of chemotherapy for stage IV gastric cancer patients: A single-institution experience

Surgery Today ◽  
2011 ◽  
Vol 41 (7) ◽  
pp. 935-940 ◽  
Author(s):  
Toshiro Okuyama ◽  
Daisuke Korenaga ◽  
Kenichi Koushi ◽  
Shinji Itoh ◽  
Hirofumi Kawanaka ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Prognostic Significance ◽  
Stage Iv ◽  
Single Institution ◽  
Stage Iv Gastric Cancer ◽  
Gastric Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document